WO2006124646A3 - Methods and compostions relating to the pharmacogenetics of different gene variants in the context of irinotecan-based therapies - Google Patents

Methods and compostions relating to the pharmacogenetics of different gene variants in the context of irinotecan-based therapies Download PDF

Info

Publication number
WO2006124646A3
WO2006124646A3 PCT/US2006/018509 US2006018509W WO2006124646A3 WO 2006124646 A3 WO2006124646 A3 WO 2006124646A3 US 2006018509 W US2006018509 W US 2006018509W WO 2006124646 A3 WO2006124646 A3 WO 2006124646A3
Authority
WO
WIPO (PCT)
Prior art keywords
abcc2
methods
compositions
irinotecan
determining
Prior art date
Application number
PCT/US2006/018509
Other languages
French (fr)
Other versions
WO2006124646A2 (en
Inventor
Mark J Ratain
Federico Innocenti
Deanna L Kroetz
Samir Undevia
Tan D Nguyen
Wanqing Liu
Original Assignee
Univ Chicago
Univ California
Mark J Ratain
Federico Innocenti
Deanna L Kroetz
Samir Undevia
Tan D Nguyen
Wanqing Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago, Univ California, Mark J Ratain, Federico Innocenti, Deanna L Kroetz, Samir Undevia, Tan D Nguyen, Wanqing Liu filed Critical Univ Chicago
Priority to US11/913,150 priority Critical patent/US20090247475A1/en
Publication of WO2006124646A2 publication Critical patent/WO2006124646A2/en
Publication of WO2006124646A3 publication Critical patent/WO2006124646A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGTlAl, and/or SLCOlBl gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGTlAl, and/or SLCOlBl substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient or predicting their efficacy. Alterations in suggested therapy may ensue based on genotyping results.
PCT/US2006/018509 2004-03-05 2006-05-12 Methods and compostions relating to the pharmacogenetics of different gene variants in the context of irinotecan-based therapies WO2006124646A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/913,150 US20090247475A1 (en) 2004-03-05 2006-05-12 Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68083905P 2005-05-13 2005-05-13
US60/680,839 2005-05-13

Publications (2)

Publication Number Publication Date
WO2006124646A2 WO2006124646A2 (en) 2006-11-23
WO2006124646A3 true WO2006124646A3 (en) 2007-08-02

Family

ID=37431931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/018509 WO2006124646A2 (en) 2004-03-05 2006-05-12 Methods and compostions relating to the pharmacogenetics of different gene variants in the context of irinotecan-based therapies

Country Status (1)

Country Link
WO (1) WO2006124646A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9072742B2 (en) 2009-04-06 2015-07-07 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to QT prolongation
US9074256B2 (en) 2009-04-06 2015-07-07 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to QT prolongation
CA2757717C (en) 2009-04-06 2018-09-04 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation
SI3023506T1 (en) 2009-04-06 2018-08-31 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
WO2005087952A1 (en) * 2004-03-05 2005-09-22 The Regents Of The University Of California Methods and compositions relating to the pharmacogenetics of abcc2, ugt1a1, and/or slc01b1 gene variants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
WO2005087952A1 (en) * 2004-03-05 2005-09-22 The Regents Of The University Of California Methods and compositions relating to the pharmacogenetics of abcc2, ugt1a1, and/or slc01b1 gene variants

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANDO Y ET AL: "polymorphisms of UDP-Glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, 15 December 2000 (2000-12-15), pages 6921 - 6926, XP002331169, ISSN: 0008-5472 *
HUANG CHING-SHAN ET AL: "Genetic factors related to unconjugated hyperbilirubinemia amongst adults.", PHARMACOGENETICS AND GENOMICS JAN 2005, vol. 15, no. 1, January 2005 (2005-01-01), pages 43 - 50, XP009081332, ISSN: 1744-6872 *
INNOCENTI F ET AL: "Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 22, no. 8, 15 April 2004 (2004-04-15), pages 1382 - 1388, XP009036291, ISSN: 0732-183X *
ITO S ET AL: "Polymorphism of the ABC Transporter Genes, MDR1, MRP1 AND MRP2/CMOAT, in Healthy Japanese Subjects", PHARMACOGENETICS, CHAPMAN & HALL, LONDON, GB, vol. 11, no. 2, March 2001 (2001-03-01), pages 175 - 184, XP009014931, ISSN: 0960-314X *
NIEMI M ET AL: "High Plasma Pravastatin Concentrations Are Associated with Single Nucleotide Polymorphisms and Haplotypes of Organic Anion Transporting Polypeptide-C (OATP-C, SLCO1B1)", PHARMACOGENETICS, CHAPMAN & HALL, LONDON, GB, vol. 14, no. 7, July 2004 (2004-07-01), pages 429 - 440, XP009039924, ISSN: 0960-314X *
NISHIZATO YOHEI ET AL: "Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics", CLINICAL PHARMACOLOGY & THERAPEUTICS, MOSBY-YEAR BOOK, ST LOUIS, MO, US, vol. 73, no. 6, June 2003 (2003-06-01), pages 554 - 565, XP002306135, ISSN: 0009-9236 *
NOZAWA TAKASHI ET AL: "Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothe cin: in vitro evidence and effect of single nucleotide polymorphisms.", DRUG METABOLISM AND DISPOSITION: THE BIOLOGICAL FATE OF CHEMICALS MAR 2005, vol. 33, no. 3, March 2005 (2005-03-01), pages 434 - 439, XP002426973, ISSN: 0090-9556 *
ROHRBACHER MAREN ET AL: "Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing.", PHARMACOGENOMICS MAR 2006, vol. 7, no. 2, March 2006 (2006-03-01), pages 167 - 176, XP009081342, ISSN: 1462-2416 *
SUZUKI H & SUGIYAMA Y: "single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 54, 18 November 2002 (2002-11-18), pages 1311 - 1331, XP002331164, ISSN: 0169-409X *

Also Published As

Publication number Publication date
WO2006124646A2 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
Taubert et al. Impact of P‐glycoprotein on clopidogrel absorption
Valiyaveettil et al. Protective efficacy of catalytic bioscavenger, paraoxonase 1 against sarin and soman exposure in guinea pigs
WO2008057459A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
WO2007024472A3 (en) USE OF PAR- l/PAR- 4 INHIBITORS FOR TREATING OR PREVENTING VASCULAR DISEASES
WO2008080082A3 (en) Methods for modulating set and uses thereof
Zuo et al. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations
WO2006087206A3 (en) Androgen receptor-dependent gene expression control by inhibiting the amine oxidase activity of lysine-specific demethylase (lsd1)
WO2008127275A3 (en) Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
WO2006071812A3 (en) Platinum iv complex inhibitor
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
ZA200809250B (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
WO2010031825A3 (en) Methods and compositions for the treatment of cancer
WO2005086768A3 (en) Enhanced production of functional proteins from defective genes
WO2006002437A3 (en) Treatment of conditions involving demyelination
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EP2543384A3 (en) Treatment of conditions involving demyelination
WO2008130619A3 (en) A composition comprising an inhibitor of pde4 and/or pde7
WO2006124646A3 (en) Methods and compostions relating to the pharmacogenetics of different gene variants in the context of irinotecan-based therapies
WO2008048121A3 (en) Macrocyclic cysteine protease inhibitors and compositions thereof
WO2007098047A3 (en) Methods and compositions for the treatment of parkinson's disease
WO2007047205A8 (en) Enzyme inhibitors of pai-1
Wang et al. Drug interactions with non–vitamin K oral anticoagulants
WO2007095250A3 (en) Compositions and methods for inhibiting optic nerve damage
WO2011072007A3 (en) Methods and compositions for detection and identification of organophosphorus nerve agents, pesticides and other toxins

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06784407

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06784407

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11913150

Country of ref document: US